Sasanlimab (PF-06801591) added to BCG therapy significantly improved outcomes for patients with BCG-naive, high-risk ...

An oncology nurse practitioner's transition from private practice to cancer research offers insights for nurses exploring new ...

Liso-Cel Shows Comparable Real-World Outcomes in Relapsed/Refractory LBCL ...

Liso-Cel Shows Comparable Real-World Outcomes in Relapsed/Refractory LBCL ...

Phase 1 data indicate invikafusp alfa's potential as a precision cancer immunotherapeutic in solid tumors that have ...

Oncology nurses and APPs should prioritize active listening and deeper patient engagement to build trusting, long-term relationships with patients with MPNs.

Liso-Cel Shows Comparable Real-World Outcomes in Relapsed/Refractory LBCL ...

Liso-Cel Shows Comparable Real-World Outcomes in Relapsed/Refractory LBCL ...

Liso-Cel Shows Comparable Real-World Outcomes in Relapsed/Refractory LBCL ...

Liso-Cel Shows Comparable Real-World Outcomes in Relapsed/Refractory LBCL ...

Panelists discuss how to help patients weigh the risks and benefits of different treatment options for paroxysmal nocturnal hemoglobinuria (PNH), outlining tools and techniques used to ensure that ...

In patients with RRMM, subcutaneous isatuximab plus Pd resulted in a non-inferior objective response rate (ORR) and comparable pre-dose concentrations at steady state compared to IV isatuximab plus Pd ...